In recent trading, Capricor Therapeutics Inc (CAPR) stock price has shown some volatility, fluctuating 101.95% over the last five trades and 111.45% over the past 30 trades. This represents a notable ...
SAN DIEGO - 专注于细胞和外泌体疗法治疗罕见疾病的生物技术公司Capricor Therapeutics (NASDAQ: CAPR)宣布计划向美国食品和药物管理局(FDA)提交其主要产品候选药物deramiocel的生物制品许可申请(BLA),用于治疗杜氏肌营养不良症(DMD)患者的心肌病。该公司预计将于2024年10月开始滚动提交流程,并在年底前完成。 这一决定是在最近与FDA讨论后 ...
Capricor Therapeutics (CAPR) shares rallied 18.2% in the last trading session to close at $5.97. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Capricor Therapeutics shares rose in premarket trading Tuesday after the company said it plans to file a biologics license application for Deramiocel, its Duchenne muscular dystrophy cardiomyopathy ...